Ionis Pharmaceuticals shares are trading higher after the company announced results from its phase 1/2 open-label study of Angelman Syndrome, which showed 97% of patients in the medium and high dose groups saw improvement in overall Angelman syndrome symptoms.
$IONS
Biotechnology: Pharmaceutical Preparations
Health Care
Ionis Pharmaceuticals shares are trading higher after the company announced results from its phase 1/2 open-label study of Angelman Syndrome, which showed 97% of patients in the medium and high dose groups saw improvement in overall Angelman syndrome symptoms.